Home » Stocks » NMTR

9 Meters Biopharma, Inc. (NMTR)

Stock Price: $1.38 USD -0.01 (-0.72%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $1.42 +0.04 (2.90%) Mar 5, 7:58 PM
Market Cap 262.16M
Revenue (ttm) n/a
Net Income (ttm) -65.44M
Shares Out 141.63M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $1.38
Previous Close $1.39
Change ($) -0.01
Change (%) -0.72%
Day's Open 1.39
Day's Range 1.20 - 1.43
Day's Volume 8,462,043
52-Week Range 0.37 - 2.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 4 days ago

RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appoi...

Zacks Investment Research - 1 month ago

9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

24/7 Wall Street - 1 month ago

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CVE, CNTY, KSHB, VIVE
InvestorPlace - 1 month ago

NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.

Accesswire - 2 months ago

Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects ...

Zacks Investment Research - 3 months ago

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Investment Research - 4 months ago

Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.

Zacks Investment Research - 5 months ago

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Benzinga - 6 months ago

Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.

PRNewsWire - 7 months ago

NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

24/7 Wall Street - 8 months ago

9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.

About NMTR

9 Meters Biopharma, a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for dev... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Sandeep Laumas
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
NMTR
Full Company Profile

Financial Performance

Financial Statements